India permits clinical trial for nasal Covid booster shot

Tribune News Service

Updated At : 08:13 PM Jan 28, 2022 IST

Unlock Exclusive Insights with The Tribune Premium

Take your experience further with Premium access. Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits

Yearly Premium ₹999 ₹349/Year

Yearly Premium $49 $24.99/Year

Aditi Tandon

New Delhi, January 28

India on Friday cleared Bharat Biotech’s intranasal Covid vaccine candidate for clinical trials as Covid booster dose.

The central licensing authority (Drug Controller General of India) granted the permission for the world’s first nasal Covid shot as a booster.

Once approved, this could be a game changer, sources said, citing the ease of vaccine delivery.

The permission to conduct clinical trials has been given for nine sites across India, including Pt BD Sharma Postgraduate Institute of Medical Sciences (PGIMS), UHS, Rothak, Haryana, AIIMS New Delhi and AIIMS Patna.

The candidate cleared for trials is Chimpanzee Adenovirus Vectored Covid Vaccine (BBV154).

The Tribune, now published from Chandigarh, started publication on February 2, 1881, in Lahore (now in Pakistan). It was started by Sardar Dyal Singh Majithia, a public-spirited philanthropist, and is run by a trust comprising five eminent persons as trustees.

The Tribune, the largest selling English daily in North India, publishes news and views without any bias or prejudice of any kind. Restraint and moderation, rather than agitational language and partisanship, are the hallmarks of the newspaper. It is an independent newspaper in the real sense of the term.

The Tribune has two sister publications, Punjabi Tribune (in Punjabi) and Dainik Tribune (in Hindi).

Remembering Sardar Dyal Singh Majithia

Designed and developed by : SORTD

Unlock Exclusive Insights with The Tribune Premium

Suggested Articles